Preserving visual acuity: a compelling 12-year case study of controlling neovascular age-related macular degeneration.

Introduction: In neovascular age-related macular degeneration (nAMD) trials, anti-VEGF injection frequency decreases after the first year, while outcomes remain primarily related to the number of injections. To the best of our knowledge, there are no reports of maintaining the best corrected visual acuity (BCVA) for more than 7 years in extension studies.

Objective: To report a 12-year follow-up of a real-world case of nAMD where BCVA was preserved from declining.